Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials

Table 2 Analysis of outcomes

	2–5 day regimen	14-day regimen	p-value
	n = 474	n = 155	p-value
Primary outcome measure
Days alive and out of hospital within 14 days, Mean (95% CI)	8.3 (7.9–8.7)	4.2 (3.6–4.9)	< 0.001
Secondary outcome measures
Cumulative median dose corticosteroids (mg)
over 6-month follow-up period (IQR)	322.5 (200–605)	560 (560–773)
Death during 6-month follow-up period
Adjusted HR (95% CI)^a	Reference	0.8 (0.4–1.5)	0.45
Death or admission to ICU during 6-month follow-up period
Adjusted OR (95% CI)^b	Reference	1.4 (0.9–2.3)	0.25
New or aggravated hypertension^b
Adjusted OR (95% CI)	Reference	1.5 (0.9–2.7)	0.15
Length of hospital stay^c
Adjusted mean days (SE)	Reference	+ 5.4 (± 0.6)	< 0.0001
Probability of discharge within 30 days^a
Adjusted HR (95% CI)	Reference	0.6 (0.5–0.70)	< 0.0001

CI confidence interval, HR hazard ratio, OR odds ratio, ICU intensive care unit, SE standard error
^aBased on Cox proportional hazards model adjusted for age, sex, smoking status, pre-treatment with antibiotics, pre-treatment with corticosteroids, and Medical Research Council dyspnoea scale
^bBased on logistic model adjusted for age, sex, smoking status, pre-treatment with antibiotics, pre-treatment with corticosteroids, and Medical Research Council dyspnoea scale
^cBased on means and standard error

ISSN: 1465-993X